Causality Assessment for Suspected DILI During Clinical Phases of Drug Development
Crossref DOI link: https://doi.org/10.1007/s40264-014-0185-4
Published Online: 2014-10-29
Published Print: 2014-11
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Regev, Arie
Seeff, Leonard B.
Merz, Michael
Ormarsdottir, Sif
Aithal, Guruprasad P.
Gallivan, Jim
Watkins, Paul B.
License valid from 2014-10-29